These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 18172786

  • 1. Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study.
    Chen L, He Y, Huang H, Liao H, Wei W.
    Med Oncol; 2008; 25(2):161-71. PubMed ID: 18172786
    [Abstract] [Full Text] [Related]

  • 2. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
    Gadgeel SM, Ruckdeschel JC, Heath EI, Heilbrun LK, Venkatramanamoorthy R, Wozniak A.
    J Thorac Oncol; 2007 Apr; 2(4):299-305. PubMed ID: 17409801
    [Abstract] [Full Text] [Related]

  • 3. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
    Reckamp KL, Krysan K, Morrow JD, Milne GL, Newman RA, Tucker C, Elashoff RM, Dubinett SM, Figlin RA.
    Clin Cancer Res; 2006 Jun 01; 12(11 Pt 1):3381-8. PubMed ID: 16740761
    [Abstract] [Full Text] [Related]

  • 4. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.
    Fidler MJ, Argiris A, Patel JD, Johnson DH, Sandler A, Villaflor VM, Coon J, Buckingham L, Kaiser K, Basu S, Bonomi P.
    Clin Cancer Res; 2008 Apr 01; 14(7):2088-94. PubMed ID: 18381949
    [Abstract] [Full Text] [Related]

  • 5. Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.
    Li N, Li H, Su F, Li J, Ma X, Gong P.
    Int J Clin Exp Pathol; 2015 Apr 01; 8(8):9010-20. PubMed ID: 26464643
    [Abstract] [Full Text] [Related]

  • 6. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
    Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G.
    Clin Cancer Res; 2003 Jun 01; 9(6):2316-26. PubMed ID: 12796401
    [Abstract] [Full Text] [Related]

  • 7. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.
    Chen Z, Zhang X, Li M, Wang Z, Wieand HS, Grandis JR, Shin DM.
    Clin Cancer Res; 2004 Sep 01; 10(17):5930-9. PubMed ID: 15355926
    [Abstract] [Full Text] [Related]

  • 8. The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells.
    Ko JC, Wang LH, Jhan JY, Ciou SC, Hong JH, Lin ST, Lin YW.
    Lung Cancer; 2009 Sep 01; 65(3):290-8. PubMed ID: 19157634
    [Abstract] [Full Text] [Related]

  • 9. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
    Dong S, Zhang XC, Cheng H, Zhu JQ, Chen ZH, Zhang YF, Xie Z, Wu YL.
    Cancer Chemother Pharmacol; 2012 Nov 01; 70(5):707-16. PubMed ID: 22941374
    [Abstract] [Full Text] [Related]

  • 10. Simultaneous blockage of epidermal growth factor receptor and cyclooxygenase-2 in a human xenotransplanted lung cancer model.
    Mu XY, Dong XL, Sun J, Ni YH, Dong Z, Li XL, Sun EL, Yi Z, Li G.
    Asian Pac J Cancer Prev; 2014 Nov 01; 15(1):69-73. PubMed ID: 24528083
    [Abstract] [Full Text] [Related]

  • 11. Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines.
    Gadgeel SM, Ali S, Philip PA, Wozniak A, Sarkar FH.
    Cancer; 2009 May 15; 115(10):2165-76. PubMed ID: 19288574
    [Abstract] [Full Text] [Related]

  • 12. Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group.
    Agarwala A, Fisher W, Bruetman D, McClean J, Taber D, Titzer M, Juliar B, Yu M, Breen T, Einhorn LH, Hanna N.
    J Thorac Oncol; 2008 Apr 15; 3(4):374-9. PubMed ID: 18379355
    [Abstract] [Full Text] [Related]

  • 13. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
    Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2003 Apr 15; 9(4):1566-72. PubMed ID: 12684433
    [Abstract] [Full Text] [Related]

  • 14. Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells.
    Park JS, Jun HJ, Cho MJ, Cho KH, Lee JS, Zo JI, Pyo H.
    Clin Cancer Res; 2006 Aug 15; 12(16):4989-99. PubMed ID: 16914589
    [Abstract] [Full Text] [Related]

  • 15. Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor.
    Gadgeel SM, Ali S, Philip PA, Ahmed F, Wozniak A, Sarkar FH.
    Cancer; 2007 Dec 15; 110(12):2775-84. PubMed ID: 17948911
    [Abstract] [Full Text] [Related]

  • 16. Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck.
    Choe MS, Chen Z, Klass CM, Zhang X, Shin DM.
    Clin Cancer Res; 2007 May 15; 13(10):3015-23. PubMed ID: 17505004
    [Abstract] [Full Text] [Related]

  • 17. Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling.
    Wang ZL, Fan ZQ, Jiang HD, Qu JM.
    Carcinogenesis; 2013 Mar 15; 34(3):638-46. PubMed ID: 23172668
    [Abstract] [Full Text] [Related]

  • 18. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA.
    Clin Cancer Res; 2006 Dec 01; 12(23):7117-25. PubMed ID: 17145836
    [Abstract] [Full Text] [Related]

  • 19. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.
    Cancer Res; 2004 Aug 01; 64(15):5355-62. PubMed ID: 15289342
    [Abstract] [Full Text] [Related]

  • 20. Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer.
    Altorki NK, Port JL, Zhang F, Golijanin D, Thaler HT, Duffield-Lillico AJ, Subbaramaiah K, Dannenberg AJ.
    Clin Cancer Res; 2005 Jun 01; 11(11):4191-7. PubMed ID: 15930356
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.